SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ARIAD Pharmaceuticals
ARIA 23.990.0%Feb 17 4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Biomaven who wrote (4303)6/7/2016 2:32:00 PM
From: tktom  Read Replies (1) of 4474
 
Yes, Criz is currently the only approved first line agent for ALK+, which is why it is the comparator against briga in the new front line trial.But alectinib will get front line approval before that trial is fully enrolled, and so it will be hard to get people to enroll in a trial where they might end up with the much inferior (criz) drug.
The path that Ariad unfortunately took was to push the dose to 240 mg to try to capture both EGFR and ALK+ at the one dose, losing 18 months in the process, and finally conceding that EGFR wasn't going to work. If they would have separated those trials, Brigatinib for ALK+ would be approved by now..
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News